Disclosures
Jen-Shi
ONCOLOGY, EVENTS, CROSS
Hironaga Satake reports research funding paid to his institution from Ono Pharmaceutical Co Ltd, Daiichi Sankyo and Taiho Pharmaceutical Co Ltd, and honoraria for lectures from Bristol Myers Squibb Co., Ltd., Bayer Co., Ltd., Chugai Pharmaceutical Co., Ltd, Daiichi Sankyo Co., Ltd., Eli Lilly Japan Co., Ltd., MSD Co., Ltd., Ono Pharmaceutical Co., Ltd., Sanofi Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Co., Ltd. and Yakult Honsha Co., Ltd.Keun-Wook Lee reports grants paid to his institution for conducting clinical trials from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, AstraZeneca, Ono Pharmaceutical Co., Ltd., Merck KGaA, Pfizer, BeiGene, Astellas Pharma, ALX Oncology, Zymeworks, Macrogenics, Five Prime Therapeutics, Seagen, Bolt Therapeutics, Trishula Therapeutics, Oncologie, Pharmacyclics, LSK BioPharma, MedPacto, Green Cross Corp, ABLBIO, Y-BIOLOGICS, Genexine, Daiichi Sankyo, Taiho Pharmaceutical, InventisBio, Leap Therapeutics and Solasia; and personal fees from ISU ABXIS, Bayer, Daiichi Sankyo, Merck Sharp and Dohme, Bristol Myers Squibb, Vifor Pharma for consultation and Ono Pharmaceutical Co., Ltd., and Boryung for honoraria.Hyun Cheol Chung reports consulting fees from Taiho, Celltrion, MSD, Eli Lilly, Bristol Myers Squibb, Merck Serono, Gloria, Beigene, Amgen and Zymework; honoraria from Merck-Serono and Eli Lilly; and that his institution received grants from Eli Lilly, GSK, MSD, Merck Serono, Bristol Myers Squibb, Ono Pharmaceutical Co., Ltd., Taiho, Amgen, Beigene, Incyte and Zymework.Jeeyun Lee reports no conflicts of interest.Kensei Yamaguchi reports receiving payment or honoraria from Taiho Pharm, Daiichi Sankyo, Eli Lilly Japan, Ono Pharmaceutical Co., Ltd., and Bristol Myers Squibb.Jen-Shi Chen reports no conflicts of interest.Takaki Yoshikawa reports lecture fees from Bristol Myers Squibb, MSD, Ono Pharmaceutical Co., Ltd., Taiho, Daiichi Sankyo, Lilly, Otsuka, Terumo, Covidien, EA Pharma, and AstraZeneca.Kenji Amagai reports research funding from MSD, Taiho Pharmaceutical, Daiichi Sankyo, Nippon Zoki Pharmaceutical and Hisamitsu Pharmaceutical.Kun-Huei Yeh reports no conflicts of interest.Masahiro Goto reports receiving grants or contracts from Chugai Pharma, Nippon Kayaku and Taiho Pharmaceutical; and fees or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Daiichi Sankyo Company, Limited, Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical, MSD K.K., Takeda Pharmaceutical Company Limited, Sumitomo Dainippon Pharma Co., Ltd., Yakult Pharmaceutical Industry Co., Ltd. and Eli Lilly Japan K.K.Yee Chao reports no conflicts of interest.Ka-On Lam reports receiving support from MSD; honoraria for lecturing and speaker bureaus from MSD, Bristol Myers Squib, Eli Lilly, Novartis, Bayer, Daiichi Sankyo, AstraZeneca, Merck, Amgen, Taiho, Sanofi; and serving as an advisory board member for MSD, Bristol Myers Squibb, Eli Lilly, Novartis, Bayer, Daiichi, Sankyo, AstraZeneca, Merck and Amgen.Shi Rong Han is an employee of MSD K.K., Tokyo, Japan.Shinichi Shiratori is an employee of and a stockholder in MSD K.K., Tokyo, Japan.Sukrut Shah is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and has stock in Merck & Co., Inc., Rahway, NJ, USA.Kohei Shitara reports employment/leadership position/advisory roles with Takeda, Pfizer, Ono Pharmaceutical Co., Ltd., MSD, Taiho Pharmaceutical, Novartis, AbbVie, GlaxoSmithKline, Daiichi Sankyo, Amgen, Boehringer Ingelheim; honoraria from Takeda and Bristol Myers Squibb; and research funding from Astellas, Ono Pharmaceutical Co., Ltd., Daiichi Sankyo, Taiho Pharmaceutical, Chugai, MSD, Medi Science, Eisai and Amgen.